Genprex, Inc.

Receive alerts
Market Cap:
$138.29 m
3.58 USD
52 weeks high
52 weeks low

In brief

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer. Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. 

Deep dive We explore the investor case for growth companies


The US FDA has given its approval to a therapy combination with EGFR inhibitor osimertinib - AstraZeneca’s Tagrisso drug

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Proactive's latest virtual event highlights a trio of rising stars in medicine and agriculture

The three companies participating in the event are medical device developer BioSig Technologies Inc, gene therapy company Genprex Inc and agriculture technology company Clean Seed Capital Group

1 week, 1 day ago